ArticlePloS one2019
An epidemiological study of visceral leishmaniasis in North East Ethiopia using serological and leishmanin skin tests.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Visceral leishmaniasis elimination in Ethiopia: insights into epidemiology, transmission, treatment access, and outcome - a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Prevalence of asymptomatic Leishmania donovani infection and associated factors in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Determinants of Leishmania infection in refugee camps in Gambella and Benishangul Gumuz regional states of Ethiopia: a matched case-control study.BMC infectious diseases · 2026Article
- Visceral leishmaniasis outbreak investigation and risk factors among communities in South Omo Zone, Southern Ethiopia, 2022-2023.Parasite epidemiology and control · 2025Article
- Prevalence of Leishmania infection in refugee camps: A serological and molecular study in Gambella and Benishangul-Gumuz, Ethiopia.PLoS neglected tropical diseases · 2025Article
- Assessing Risk Factors for Visceral Leishmaniasis Outbreak in South Omo Zone, Southern Ethiopia: Implications for Tailored Intervention Strategies.Journal of multidisciplinary healthcare · 2025Article
- Sero-Prevalence of Visceral Leishmaniasis and Associated Risk Factors among Febrile Patients Attending Metema Hospital, West Gondar Zone, North West Ethiopia.Acta parasitologica · 2024Article
- Demographic characteristics and prevalence of asymptomaticFrontiers in epidemiology · 2024Article
- Sero-prevalence of visceral leishmaniasis and its associated factors among asymptomatic individuals visiting Denan health center, southeastern Ethiopia.Tropical diseases, travel medicine and vaccines · 2023Article
- Visceral Leishmaniasis in Ardabil Province, Northwest of Iran: A Retrospective Epidemiological, Clinical and Paraclinical Study (1985-2018).Iranian journal of public health · 2022Article
- Identification of asymptomatic Leishmania infections: a scoping review.Parasites & vectors · 2022Article
- Seroprevalence of visceral leishmaniasis and its associated factors among asymptomatic pastoral community of Dire District, Borena zone, Oromia Region, Ethiopia.Frontiers in public health · 2022Article
- A review of the leishmanin skin test: A neglected test for a neglected disease.PLoS neglected tropical diseases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Ethiopia, visceral leishmaniasis (VL) is caused by Leishmania donovani. The estimated country-wide incidence of VL in Ethiopia is 3700-7400 cases/year. The balance between anthroponotic and zoonotic transmission is still unknown even though most authors believe that visceral leishmaniasis in East Africa is anthroponotic. Asymptomatic leishmania infections occur more frequently than clinically apparent visceral leishmaniasis cases. The aim of this study was to determine the prevalence of asymptomatic VL infection and assess the degree of exposure among residents in Raya Azebo Woreda villages where cases of VL were recently reported.
methodsA community based cross-sectional survey was conducted in 2013 between 1st of May and 25th of July. A total of 1099 individuals living in 314 households were included in the study. Socio-demographic and clinical data were collected from each of the participants and venous blood was also collected for the detection of antibodies to visceral leishmaniasis using Direct Agglutination Test. Leishmanin skin test was performed to detect the exposure to the parasite. Data was entered into excel and exported to SPSS version 17 for statistical analysis. Chi-square and the corresponding p-values were used to determine the statistical significance of the proportions/ratios obtained from the cross tabulated data. A p-value < 0.05 was considered statistically significant.
resultA total of 1099 study subjects comprising 401 males and 698 females were included in the study. The overall positive leishmanian skin test and sero-prevalence rates respectively were 9.08% and 0.87%. The difference in LST positivity by age group and sero-prevalence by sex were statistically significant (P <0.01 and P<0.05 respectively). Out of the 9 sero-positive individuals, 7 had no history of travel to visceral leishmaniasis endemic areas out of Raya Azebo.
conclusionIn general our results suggest occurrence of VL in the study area is, very low. Our survey also indicates that due to the low incidence of the disease, and lack of awareness, some patients remain under diagnosed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.